Two weeks ago, results from Phase I/II study in which patients with metastatic urothelial cancer – whose disease progressed after platinum-based standard chemotherapy and after immunotherapy – responded to treatment with a new drug that still has no commercial name: Sacituzumab Govitecan, IMMU-132 or SN38.
There are almost no treatments to offer to patients with metastatic urothelial cancer who have failed on Platinum-based chemotherapy and immunotherapy. Therefore, these results encourage and give new hope to these patients.
IMMU-132 is a a monoclonal antibody targeting Trop-2, an epithelial cell surface antigen overexpressed in urothelial cancer.
45 patients joined the study and received IMMU-132.
47% of patients responded: In 7 patients the disease was stopped, in 12 the metastases have shrunk and in 2 patients… yes, yes … the metastases disappeared and they reached full remission!
Following these amazing results, a follow-up Phase II study was launched in the US and will recruit 140 patients.
Want to check your suitability for this and other trials that can work for you?
TRIAL•IN Pharma offers a unique, personalized test for patients with metastatic cancer and brain tumors, which reveals innovative and innovative oncologic treatments around world and helps to achieve them.
For a free Service Assessment, dial 24/7
Do not give up on life!
For further reading
https://meetinglibrary.asco.org/record/170545/abstract
